Primary assessment method
Number of patients screened18
Number of patients enrolled14
Number of patients evaluable for toxicity14
Number of patients evaluated for efficacy14
Evaluation methodRECIST 1.1
Response assessment, CR0 (0%)
Response assessment, PR2 (2%)
Response assessment, SD7 (50%)
Response assessment, PD5 (35.7%)
Median duration assessments, PFS5.5 months (95% CI: 3.8—not reached)
Median duration assessments, OS13.3 months (95% CI: 8.8—not reached)
Primary assessment method
Number of patients screened18
Number of patients enrolled14
Number of patients evaluable for toxicity14
Number of patients evaluated for efficacy14
Evaluation methodRECIST 1.1
Response assessment, CR0 (0%)
Response assessment, PR2 (2%)
Response assessment, SD7 (50%)
Response assessment, PD5 (35.7%)
Median duration assessments, PFS5.5 months (95% CI: 3.8—not reached)
Median duration assessments, OS13.3 months (95% CI: 8.8—not reached)
Primary assessment method
Number of patients screened18
Number of patients enrolled14
Number of patients evaluable for toxicity14
Number of patients evaluated for efficacy14
Evaluation methodRECIST 1.1
Response assessment, CR0 (0%)
Response assessment, PR2 (2%)
Response assessment, SD7 (50%)
Response assessment, PD5 (35.7%)
Median duration assessments, PFS5.5 months (95% CI: 3.8—not reached)
Median duration assessments, OS13.3 months (95% CI: 8.8—not reached)
Primary assessment method
Number of patients screened18
Number of patients enrolled14
Number of patients evaluable for toxicity14
Number of patients evaluated for efficacy14
Evaluation methodRECIST 1.1
Response assessment, CR0 (0%)
Response assessment, PR2 (2%)
Response assessment, SD7 (50%)
Response assessment, PD5 (35.7%)
Median duration assessments, PFS5.5 months (95% CI: 3.8—not reached)
Median duration assessments, OS13.3 months (95% CI: 8.8—not reached)
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close